Smoking Cessation and Addiction Treatments A World Market Analysis

Smoking cessation is an increasingly important area of focus for pharmaceutical companies, healthcare entities and governments. There are 1.4 billion smokers in the world, and with smoking is a known cause of heart disease, lung cancer, respiratory infections and many other diseases. This has created a large market for smoking cessation aids.

The market that Zyban holds a lock on is ready for change with a major new brand ready to shake up the current market share. But the high incidence of smoking and with strong public-sector goals to reduce smoking create a robust potential for new entrants. The market for treatments for alchohol and drug abuse, now dominated by Subutex and Campral, will also see growth and a robust line of new products.

Kalorama's Smoking Cessation and Addiction Treatments: A World Market Analysis covers the market for pharmaceuticals that assist with smoking cessation and addiction treatment.

Using information gathered for Kalorama's larger report on Psychotherapeutics: the World Market and interviews with psychotherapeutic industry insiders therein, this report takes a more detailed look at the combined market for both smoking cessation and alchohol/drug addiction treatments. The report includes:

Round-up of current products available.

Market share of major players and brands.

Forecasts revenues to 2010.

Current revenues for 2005.

World incidence data for Nictotine Addiction, Drug Addiction and Alchohol Abuse.

Reviews of new products in the pipeline.

Key trends driving pharmaceutical treatments for smoking cessation and drug addiction.

Product managers, business development executives, marketing managers, as well as executives in financial and advertising companies, are among those who will find this report a useful resource.

Apr 1, 2007

68 Pages

PDF Format
Table of Contents
Price: $1,495.00 / GBP747.50